Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-04-15
2008-09-16
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S267000, C544S118000, C544S270000, C544S273000, C544S269000
Reexamination Certificate
active
07425560
ABSTRACT:
There is disclosed the use of a compound of formula (Ia) or (Ib) wherein R1, R2, R3, R4, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (Ia) or (Ib) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (Ia) and (Ib) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.
REFERENCES:
patent: 3135753 (1964-06-01), Hitchings et al.
patent: 4710503 (1987-12-01), Hofer
patent: 4820709 (1989-04-01), Hofer
patent: 5173491 (1992-12-01), Kamoun et al.
patent: 5489598 (1996-02-01), Connor et al.
patent: 5716967 (1998-02-01), Kleinman
patent: 5756511 (1998-05-01), West et al.
patent: 5976823 (1999-11-01), Wu
patent: 6025361 (2000-02-01), Cavalla et al.
patent: 6046019 (2000-04-01), Goumeniouk et al.
patent: 6066641 (2000-05-01), Cavalla et al.
patent: 6294541 (2001-09-01), Cavalla et al.
patent: 6319928 (2001-11-01), Chasin et al.
patent: 7108997 (2006-09-01), Kettle
patent: 2004/0022871 (2004-02-01), Mainnemare
patent: 2004/0029871 (2004-02-01), Kettle et al.
patent: 2005/0070558 (2005-03-01), Vidal Juan et al.
patent: 2007/0032468 (2007-02-01), Kettle et al.
patent: 2007/0093483 (2007-04-01), Svensson et al.
patent: 1013676 (1991-08-01), None
patent: 1013676 (1991-08-01), None
patent: 0010531 (1980-04-01), None
patent: 0359505 (1990-03-01), None
patent: 0430300 (1991-06-01), None
patent: 0452926 (1996-03-01), None
patent: 01016407 (2000-07-01), None
patent: 02160235 (1990-06-01), None
patent: 8906125 (1989-07-01), None
patent: 95/00516 (1995-01-01), None
patent: WO 9618400 (1996-06-01), None
patent: 9914204 (1999-03-01), None
patent: 9917773 (1999-04-01), None
patent: WO 9936073 (1999-07-01), None
patent: 9940091 (1999-08-01), None
patent: 0051598 (2000-09-01), None
patent: 0059449 (2000-10-01), None
patent: WO 0185146 (2001-11-01), None
patent: 0208237 (2002-01-01), None
patent: 02006272 (2002-01-01), None
patent: 02066447 (2002-08-01), None
patent: 02090575 (2002-11-01), None
patent: 03000694 (2003-01-01), None
patent: 03082873 (2003-10-01), None
patent: 2004096781 (2004-11-01), None
patent: 2005037835 (2005-04-01), None
patent: 2005042534 (2005-05-01), None
patent: 2005077950 (2005-08-01), None
patent: 2006045564 (2006-05-01), None
patent: 2006046910 (2006-05-01), None
patent: 2006062465 (2006-06-01), None
patent: 2007142576 (2007-12-01), None
Garst, G. L. Kramer, Y. J. Wu, and J. N. Wells, J. Med. Chem.; 1976; 19(4) pp. 499-503.
van Galen et al. Mol Pharmacol 45 (6): 1101 (1994).
Peter W. K. Woo, et al., J. Med. Chem.; 1992; 35(8) pp. 1451-1457.
Armitage et al., British Journal of Pharmacology and Chemotherapy (1961), 17, 196-207.
Armitage et al., “Structure-Activity Relationships in a Series of 6-Thioxanthines with Bronchodilator and Coronary Dilator Properties,” British Journal of Pharmacology and Chemotherapy (1961), vol. 17, pp. 196-207.
Wooldridge et al., “The Synthesis of Some 6-Thioxanthines,” J. Chem. Soc., 1962, pp. 1863-1868.
Garst et al., “Inhibition of Separated Forms of Phosphodiesterases from Pig Coronary Arteries by Uracils and by 7-Substituted Derivatives of 1-Methyl-3-isobutylxanthine,” J. Med. Chem.; 1976; vol. 19(4) pp. 499-503.
Katritzky et al., “A General Method for the N-Alkylation of Thioamides,” Tetrahedron Letters, (1988), vol. 29(15), pp. 1755-1758.
Merlos et al., “Structure-Activity Relationships in a Series of Xanthine Derivatives with Antibronchoconstrictory and Bronchodilatory Activities,” Eur. J. Med .Chem. Chim. Ther., 1990, vol. 25, pp. 653-658.
Woo et al., “Inhibitors of Human Purine Nucleoside Phosphorylase. Synthesis and Biological Activities of 8-Amino-3-benzylhypoxanthine and Related Analogues,” J. Med. Chem., 1992; vol. 35, pp. 1451-1457.
Van Der Goot et al., “Isothiourea Analogues of Histamine as Potent Agonists or Antagonists of the Histamine H3-Receptor,” Eur. J. Med. Chem., 1992, vol. 27, pp. 511-517.
Van Galen et al., “A Binding Site Model and Structure-Activity Relationships for the Rat A3 Adenosine Receptor,” Molecular Pharmacology, 1994, vol. 45, pp. 1101-1111.
Jacobson et al., “1,3-Dialkylxanthine Derivatives Having High Potency as Antagonists at Human A2B Adenosine Receptors,” Drug Development Research, 1999, vol. 47, pp. 45-53.
English abstract for CN1013676, STN International CAPLUS 1986:626214.
International Search Report issued for PCT/SE03/00617, issued on Aug. 5, 2003.
Aaron, S D et al., “Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbation of Chronic Obstructive Pulmonary Disease,” Am J Respir Crit Care Med., 2001, pp. 349-355, vol. 163.
Akbiyik et al., “In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil,” Eur. J. Clin. Pharmacol., 2001, vol. 57, pp. 631-636.
Baldus, S. et al., “Myeloperoxidase Serum Levels Predict Risk in Patients with Acute Coronary Syndromes,” Circulation, 2003, pp. 1440-1445, vol. 108.
Berlow et al., “The Effect of Dapsone in Steroid-Dependent Asthma,” 1991, J. Allergy Clin. Immunol., 1991, vol. 87 (3), pp. 710-715.
Bozeman et al., “Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone,” Biochemical Pharmacology, 1992, vol. 44, No. 3, pp. 553-563.
Brennan, M. et al., “Prognostic Value of Myeloperoxidase in Patients with Chest Pain,” N Engl J Med., 2003, pp. 1595-1604, vol. 349, No. 17.
Choi, D-K et al., “Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice,” J. Neurosci., 2005, pp. 6594-6600, vol. 25, No. 28.
Crooks, S W et al., “Bronchial Inflammation in Acute Bacterial Exacerbations of Chronic Bronchitis: the Role of Leukotriene B4,” European Respiratory Journal, 2000, pp. 274-280, vol. 15, No. 2.
Cuzner, M L et al., “Plasminogen Activators and Matrix Metalloproteases, Mediators of Extracellular Proteolysis in Inflammatory Demyelination of the Central Nervous System,” Journal of Neuroimmunology, 1999, pp. 1-14, vol. 94, No. 1-2.
Dallegri et al., Possible Modes of Action of Nimesulide in Controlling Neutrophilic Inflammation, Arzneimittel-Foschung/Drug Research, 1995, vol. 45(II), No. 10, pp. 1114-1117.
Daugherty, A. et al., “Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerotic Lesions,” J Clin Invest., 1994, pp. 437-444, vol. 94, No. 1.
Fiorini, G. et al., “Serum ECP and MPO are Increased During Exacerbations of Chronic Bronchitis with Airway Obstruction,” Biomedicine & Pharmacotherapy, 2000, pp. 274-278, vol. 54.
Green, P S et al., “Neuronal Expression of Myeloperoxidase is Increased in Alzheimer's Disease,” Journal of Neurochemistry, 2004, pp. 724-733, vol. 90, No. 3.
Grisham et al., “Assessment of Leukocye involvement during Ischemia and Reperfusion of Intestine,” Am. J. Physiol., 1986, vol. 251, pp. 729-742.
Hampton, M B, et al., “Inside the Neutrophil Phagosome: Oxidants, Myeloperoxidase, and Bacterial Killing,” Blood, 1998, pp. 3007-3017, vol. 92, No. 9.
Hope et al., “Large scale purification of myeloperoxidase from HL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase,” Protein Expression and Purification, 2000, vol. 18, pp. 269-276.
Kettle et al., “Assays for the Chlorination Activity of Myeloperoxidase,” Biophyl, 1992, vol. 296, pp. 502-512.
Kettle et al., “Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs,” Biochemical Pharmacology, 1991, vol. 41, No. 10, pp. 1485-1492.
Kettle et al., “Superoxide is an Antagon
AstraZeneca AB
Berch Mark L
Cohen Jacqueline
LandOfFree
Thioxanthine derivatives as myeloperoxidase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thioxanthine derivatives as myeloperoxidase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thioxanthine derivatives as myeloperoxidase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3987472